Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs
Buzdin A. A., Sorokin M. I., Garazha A., Sekacheva M. I., Kim E., Zhukov N., Wang Y., Li X., Kar S., Hartmann C., Samii A., Giese A., Borisov N. M.
Seminars in Cancer Biology
Vol.53, P. 110-124
Опубликовано: 2018
Тип ресурса: Обзор
DOI:10.1016/j.semcancer.2018.06.003
Аннотация:
Anticancer target drugs (ATDs) specifically bind and inhibit molecular targets that play important roles in cancer development and progression, being deeply implicated in intracellular signaling pathways. To date, hundreds of different ATDs were approved for clinical use in the different countries. Compared to previous chemotherapy treatments, ATDs often demonstrate reduced side effects and increased efficiency, but also have higher costs. However, the efficiency of ATDs for the advanced stage tumors is still insufficient. Different ATDs have different mechanisms of action and are effective in different cohorts of patients. Personalized approaches are therefore needed to select the best ATD candidates for the individual patients. In this review, we focus on a new generation of biomarkers – molecular pathway activation – and on their applications for predicting individual tumor response to ATDs. The success in high throughput gene expression profiling and emergence of novel bioinformati
Ключевые слова:
Anticancer target drugs; Big data analytics; Bioinformatics; Biomarkers; Cancer; Epigenetics; Gene expression; Intracellular molecular pathways; Machine learning; Micro RNA; miR; Proteomics; Response to cancer therapy; Systems biology; Transcriptomics
antineoplastic agent; tumor marker; antineoplastic agent; tumor marker; advanced cancer; bioinformatics; cancer chemotherapy; cancer growth; cancer staging; drug efficacy; drug targeting; gene activation; gene expression profiling; high throughput screening; human; learning algorithm; machine learning; malignant neoplasm; molecular biology; molecular medicine; molecularly targeted therapy; morphology; nonhuman; oncology; personalized medicine; prediction; Review; scoring system; signal transduction; treatment response; antagonists and inhibitors; drug effect; gene expression regulation; genetics; molecularly targeted therapy; neoplasm; personalized medicine; procedures; Antineoplastic Agents; Biomarkers, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Neoplasms; Precision Medicine; Signal Transduction
Язык текста: Английский
ISSN: 1096-3650
Buzdin A. A. Anton Aleksandrovich 1977-
Sorokin M. I. Maksim Igorevich 1989-
Garazha A.
Sekacheva M. I. Marina Igorevna 1976-
Kim E.
Zhukov N.
Wang Y.
Li X.
Kar S.
Hartmann C.
Samii A.
Giese A.
Borisov N. M. Nikolay Mikhaylovich 1973-
Буздин А. А. Антон Александрович 1977-
Сорокин М. И. Максим Игоревич 1989-
Гаража А.
Секачева М. И. Марина Игоревна 1976-
Ким Е.
Жуков Н.
Wанг Y.
Ли Х.
Кар С.
Хартманн C.
Самии А.
Гиесе А.
Борисов Н. М. Николай Михайлович 1973-
Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs
Текст визуальный непосредственный
Seminars in Cancer Biology
Academic Press
Vol.53 P. 110-124
2018
Обзор
Anticancer target drugs Big data analytics Bioinformatics Biomarkers Cancer Epigenetics Gene expression Intracellular molecular pathways Machine learning Micro RNA miR Proteomics Response to cancer therapy Systems biology Transcriptomics
antineoplastic agent tumor marker antineoplastic agent tumor marker advanced cancer bioinformatics cancer chemotherapy cancer growth cancer staging drug efficacy drug targeting gene activation gene expression profiling high throughput screening human learning algorithm machine learning malignant neoplasm molecular biology molecular medicine molecularly targeted therapy morphology nonhuman oncology personalized medicine prediction Review scoring system signal transduction treatment response antagonists and inhibitors drug effect gene expression regulation genetics molecularly targeted therapy neoplasm personalized medicine procedures Antineoplastic Agents Biomarkers, Tumor Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Molecular Targeted Therapy Neoplasms Precision Medicine Signal Transduction
Anticancer target drugs (ATDs) specifically bind and inhibit molecular targets that play important roles in cancer development and progression, being deeply implicated in intracellular signaling pathways. To date, hundreds of different ATDs were approved for clinical use in the different countries. Compared to previous chemotherapy treatments, ATDs often demonstrate reduced side effects and increased efficiency, but also have higher costs. However, the efficiency of ATDs for the advanced stage tumors is still insufficient. Different ATDs have different mechanisms of action and are effective in different cohorts of patients. Personalized approaches are therefore needed to select the best ATD candidates for the individual patients. In this review, we focus on a new generation of biomarkers – molecular pathway activation – and on their applications for predicting individual tumor response to ATDs. The success in high throughput gene expression profiling and emergence of novel bioinformati